{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-24-000063","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.925414+00:00","generated_at":"2026-06-01T09:01:28.462618+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"ANI Pharmaceuticals shareholders approve Amended 2022 Stock Plan, re-elect directors","bullets":["At May 21 annual meeting, all eight director nominees elected; Thomas Haughey received 14.8M for, 2.1M against.","Shareholders ratified EisnerAmper as auditor for FY2024: 18.0M for, 56.7K against.","Advisory say-on-pay approved: 16.1M for, 762.7K against, 1.2M broker non-votes.","Amended 2022 Stock Incentive Plan approved: 16.0M for, 871.2K against, 1.2M broker non-votes.","Plan increases equity pool; forms for director (1-yr cliff) and employee (4-yr graded) restricted stock filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-24-000063","json":"https://secwatch.observer/filing/0001023024-24-000063.json","markdown":"https://secwatch.observer/filing/0001023024-24-000063.md","text":"https://secwatch.observer/filing/0001023024-24-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000063/0001023024-24-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000063/ani-20240521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:01:28.462618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}